FDA approves new antibacterial drug Zerbaxa
The FDA approved Zerbaxa (ceftolozane/tazobactam), a new antibacterial drug product, to treat adults with complicated intra-abdominal infections (cIAI) and complicated urinary tract infections. Zerbaxa and Sivextro are marketed by Cubist Pharmaceuticals, based in Lexington, Mass. December 19, 2014